Thrombocytopenia Treatment Market

Thrombocytopenia Treatment Market Latest Trends
and Developments
Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The
major causes of thrombocytopenia are inefficient production of platelets, platelet splenic
sequestration, and accelerative destruction of platelets. The most common ineffective production
of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and
aplastic anemia. Thrombocytopenia can be inherited or acquired. In 2014, According to a
research article published in Professional Med J, 2014, entitled Frequency of Thrombocytopenia,
the frequency of thrombocytopenia is higher for people aged 60 years and above, suffering from
non-cirrhotic liver disease. However, rampant discovery coupled with the ability to clone
thrombopoietin has resulted in new treatment opportunities for clinical manifestation.
Get Sample Copy At @
Global Thrombocytopenia Treatment Market Taxonomy:
By Drug Class:
• Glucocorticoids
• Lysosomal Enzyme
• Platelet Stimulating Agent
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Approval of effective and safe drugs for thrombocytopenia treatment to provide momentum to
the thrombocytopenia treatment market
More specific treatment plans usually depend on the underlying etiology of thrombocytopenia.
In most cases the underlying cause of thrombocytopenia is not known, especially in the case of
severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable, small molecule
thrombopoietin (TPO) receptor agonist developed by Shionogi Inc., received approval by
Pharmaceuticals and Medical Devices Agency of Japan. Lusutrombopag helped enhance chronic
liver disease (CLD) associated with thrombocytopenia for patients scheduled to undergo invasive
procedures. Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and
stimulates signaling pathways that trigger the proliferation and differentiation of bone marrow
cells into megakaryocytes. Thus, increasing the blood platelet count. However, patients treated
with Lusustrombopag further showed higher counts of blood leukocytes and erythrocyte.
Furthermore, in June 2017, FDA accepted application for new oral investigational drug,
Tavalisse (fostamatinib disodium), by Rigel Pharmaceuticals, Inc. This drug is designed to
inhibit the spleen tyrosine kinase and treat patients suffering from chronic or persistent immune
Report includes chapters which deeply display the following deliverable about industry :
• Thrombocytopenia Treatment Market Research Objective and Assumption
• Thrombocytopenia Treatment Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Thrombocytopenia Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Thrombocytopenia Treatment Market, By Regions
• Thrombocytopenia Treatment Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Thrombocytopenia Treatment Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Thrombocytopenia Treatment Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Thrombocytopenia Treatment Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Browse Complete Report For More Information @
Another drug Eltrombopag by Novartis, an oral, non-peptide thrombopoietin receptor agonist
has shown efficacy and safety for patients suffering from chronic immune thrombocytopenia
(CIT). The use of this drug is approved in the U.S and registered in Europe. The low dose of
Eltrombopag is effective and safe for the prevention of CIT. Case Reports Hematology, 2017,
reports that long-term usage of thrombopoetin (TPO) receptor agonists is safe for patients
suffering from chronic lymphocytic leukemia associated with Immune thrombocytopenia, as they
are a non-immunosuppressive drugs.
Global Thrombocytopenia Treatment Market Dynamics
The thrombocytopenia treatment market is driven by increasing prevalence of thrombocytopenia
globally. The risk of developing thrombocytopenia is much higher for chronic Hepatitis C cases.
In 2014, according to World Health Organization (WHO), the prevalence of Hepatitis C was
lower in Americas and Europe as compared to Africa and Pakistan, where the prevalence of
chronic liver disorder was 4-6 % higher than that in Americas and Europe. Liver disease has
become a socio economic and global health problem, as 60-80% of the population develops the
disease. Furthermore, increasing government support for fast-track approval to discover newer
treatments for this disorder and increasing investment in the development of new drugs by
biotechnology and pharmaceutical companies are expected to propel growth of the
thrombocytopenia treatment market during the forecast period. However, from 2023,
thrombocytopenia treatment market is projected to witness a slowdown in growth due to patent
expiration and increasing availability of generics of Promacta and MabThera.
Global Thrombocytopenia Treatment Market – Competitors
Major players in thrombocytopenia treatment market include 3SBio Inc., Amarillo Biosciences,
Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers
Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas
Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics
GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel
Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.
To Get Instant Access, Purchase Report Here @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets.